Experimental Medicine Training Initiative
  log in
  log in
Cambridge University
Cambridge University


Cancer Drug Discovery and Development

05/03/2019 to 05/03/2019

To understand cancer drug discovery and development through a range of lectures, panel discussions and case studies.


Day 1 | Tuesday 05 March 2019

Time Item
09:30 to 10:00 Registration and Refeshments
10:00 to 10:05 Welcome
Professor Duncan Jodrell, EMIT, University of Cambridge
10:00 to 10:30 Introduction to the drug development paradigm
Andrew Foxley, Senior Director Scientific Project Management Oncology Translational Medicine Unit, Early Clinical Development Innovative Medicines, AstraZeneca
10:30 to 10:55 Cell Therapy Target Validation and “Hit ID” in Oncology
Dr Mark Creighton-Gutteridge, Director, Head of Discovery and New Technologies, Oncology Cell Therapy R&D, GlaxoSmithKline. Recommended Reading: GOTTSCHALK ET AL. CANCER J. 2014; 20(2): 151–155. DOI:10.1097/PPO.0000000000000032
10:55 to 11:20 Pre-clinical development (toxicology/PK/PD)
James Yates Principal Scientist applying Quantitative Systems Pharmacology at AstraZeneca
11:20 to 11:45 Pharmacological Audit Trail in Cancer Drug Development
Dr Simon Pacey, Clinical Senior Research Associate Academic Consultant in Cancer Therapeutics, Department of Oncology, University of Cambridge. Reading: Critical parameters in targeted drug development: the pharmacological audit trail. Banerji and Workman. Semin Oncol 2016 https://www.ncbi.nlm.nih.gov/pubmed/27663475
11:45 to 12:15 Panel discussion
12:15 to 13:30 Lunch and student posters
13:30 to 14:00 Adaptive Trial Design
Dr Steven Fox, Principal Statistician, ECD Biometrics Oncology, AstraZeneca
14:00 to 14:30 Drug combinations
Professor Duncan Jodrell, Professor of Cancer Therapeutics Director Cambridge Cancer Trials Centre (CCTC), Department of Oncology, University of Cambridge
14:30 to 14:50 Imaging biomarkers of treatment response: from RECIST to functional and molecular imaging
Dr Ferdia Gallagher, Cancer Research UK Clinician Scientist Fellow, Reader in Molecular Imaging, Department of Radiology University of Cambridge. Recommended Reading: Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol. 2017 Mar;14(3):169-186.
14:50 to 15:15 Panel discussion
15:15 to 15:45 Break
15:45 to 16:05 The immuno-oncology revolution: A clinical overview
Dr Au Lewis, Translational Research Scientist, Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute.
16:00 to 16:25 A Case Study: Durvalumab
Dr Robert Wilkinson, Director, Oncology Research, AstraZeneca
16:25 to 16:45 Immuno-oncology combinations
Dr Simon Dovedi, Group Leader Immuno-oncology, AstraZeneca & Honorary Senior Visiting Fellow in the Department of Oncology, University of Cambridge.
16:45 to 17:30 Panel discussion and closing remarks
17:30 to 19:00 Drinks reception
19:00 to 22:30 Dinner


Meeting Details

Trinity Hall

  CPD Points

 Book Now!


Forthcoming Meetings

Renal Drug Discovery and Development

30/05/2019 to 30/05/2019





Copyright ©2019 Experimental Medicine Training Initiative - Cambridge University Hospitals. All rights reserved.